{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T22:38:12Z","timestamp":1787870292026,"version":"build-2784847793"},"reference-count":52,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R61AI49665"],"award-info":[{"award-number":["R61AI49665"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01AI48055"],"award-info":[{"award-number":["U01AI48055"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1AI120176"],"award-info":[{"award-number":["UM1AI120176"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.xphs.2021.10.007","type":"journal-article","created":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T20:59:52Z","timestamp":1634677192000},"page":"529-541","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Physiologically Based Pharmacokinetic Modeling of 3 HIV Drugs in Combination and the Role of Lymphatic System after Subcutaneous Dosing. Part 1: Model for the Free-Drug Mixture"],"prefix":"10.1016","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4498-7823","authenticated-orcid":false,"given":"Simone","family":"Perazzolo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9207-3378","authenticated-orcid":false,"given":"Laura M.","family":"Shireman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4519-303X","authenticated-orcid":false,"given":"Danny D.","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney J.Y.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.xphs.2021.10.007_bib0001","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1073\/pnas.1318249111","article-title":"Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues","volume":"111","author":"Fletcher","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7588","key":"10.1016\/j.xphs.2021.10.007_bib0002","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nature16933","article-title":"Persistent HIV-1 replication maintains the tissue reservoir during therapy","volume":"530","author":"Lorenzo-Redondo","year":"2016","journal-title":"Nature"},{"issue":"Suppl 3","key":"10.1016\/j.xphs.2021.10.007_bib0003","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1097\/01.aids.0000327511.76126.b5","article-title":"The role of secondary lymphatic tissue in immune deficiency of HIV infection","volume":"22","author":"Schacker","year":"2008","journal-title":"AIDS"},{"issue":"6418","key":"10.1016\/j.xphs.2021.10.007_bib0004","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/362355a0","article-title":"HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease","volume":"362","author":"Pantaleo","year":"1993","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.xphs.2021.10.007_bib0005","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1097\/QAD.0000000000001405","article-title":"Long-acting combination anti-HIV drug suspension enhances and sustains higher drug levels in lymph node cells than in blood cells and plasma","volume":"31","author":"Kraft","year":"2017","journal-title":"AIDS"},{"issue":"5","key":"10.1016\/j.xphs.2021.10.007_bib0006","first-page":"1789","article-title":"Integration of computational and experimental approaches to elucidate mechanisms of first-pass lymphatic drug sequestration and long-acting pharmacokinetics of the injectable triple-HIV drug combination TLC-ART 101","volume":"109","author":"Perazzolo","year":"2020","journal-title":"JPharmSci"},{"issue":"5","key":"10.1016\/j.xphs.2021.10.007_bib0007","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1003586","article-title":"Mathematical modeling reveals kinetics of lymphocyte recirculation in the whole organism","volume":"10","author":"Ganusov","year":"2014","journal-title":"PLoS Comput Biol"},{"issue":"2","key":"10.1016\/j.xphs.2021.10.007_bib0008","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1021\/mp400464s","article-title":"The lymphatic system plays a major role in the intravenous and subcutaneous pharmacokinetics of trastuzumab in rats","volume":"11","author":"Dahlberg","year":"2014","journal-title":"Mol Pharm"},{"key":"10.1016\/j.xphs.2021.10.007_bib0009","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jconrel.2018.02.003","article-title":"Mechanism-based pharmacokinetic (MBPK) models describe the complex plasma kinetics of three antiretrovirals delivered by a long-acting anti-HIV drug combination nanoparticle formulation","volume":"275","author":"Kraft","year":"2018","journal-title":"J Controll Rel"},{"issue":"1","key":"10.1016\/j.xphs.2021.10.007_bib0010","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1089\/aid.2014.0210","article-title":"Anti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates","volume":"31","author":"Freeling","year":"2015","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"12","key":"10.1016\/j.xphs.2021.10.007_bib0011","first-page":"3153","article-title":"Three HIV drugs, atazanavir, ritonavir, and tenofovir, coformulated in drug-combination nanoparticles exhibit long-acting and lymphocyte-targeting properties in nonhuman primates","volume":"107","author":"Perazzolo","year":"2018","journal-title":"JPharmSci"},{"issue":"5","key":"10.1016\/j.xphs.2021.10.007_bib0012","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1128\/AAC.02748-13","article-title":"Novel liquid chromatography-tandem mass spectrometry method for simultaneous detection of anti-HIV drugs Lopinavir, Ritonavir, and Tenofovir in plasma","volume":"58","author":"Koehn","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.xphs.2021.10.007_bib0013","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1080\/02648725.2018.1471641","article-title":"Combating the HIV reservoirs","volume":"34","author":"van","year":"2018","journal-title":"Biotechnol Genet Eng Rev"},{"issue":"6","key":"10.1016\/j.xphs.2021.10.007_bib0014","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/ar.20681","article-title":"Lymph circulation in the liver","volume":"291","author":"Ohtani","year":"2008","journal-title":"Anat Rec"},{"key":"10.1016\/j.xphs.2021.10.007_bib0015","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3389\/fphys.2019.00251","article-title":"Renal lymphatics: anatomy, physiology, and clinical implications","volume":"10","author":"Russell","year":"2019","journal-title":"Front Physiol"},{"issue":"Supplement","key":"10.1016\/j.xphs.2021.10.007_bib0016","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1537\/ase.102.Supplement_165","article-title":"The lymphatics of Japanese macaque","volume":"102","author":"Hayakawa","year":"1994","journal-title":"Anthropol Sci"},{"issue":"1","key":"10.1016\/j.xphs.2021.10.007_bib0017","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1208\/s12248-015-9819-4","article-title":"A bottom-up whole-body physiologically based pharmacokinetic model to mechanistically predict tissue distribution and the rate of subcutaneous absorption of therapeutic proteins","volume":"18","author":"Gill","year":"2016","journal-title":"AAPS J"},{"issue":"11","key":"10.1016\/j.xphs.2021.10.007_bib0018","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1292\/jvms.11-0207","article-title":"Quantitative analyses of lymphoid tissue in the spleen, lymph nodes and peyer's patches in cynomolgus monkeys","volume":"73","author":"Moriyama","year":"2011","journal-title":"J Vet Med Sci"},{"issue":"3","key":"10.1016\/j.xphs.2021.10.007_bib0019","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1148\/radiology.165.3.3317494","article-title":"Lymph nodes of the neck","volume":"165","author":"Som","year":"1987","journal-title":"Radiology"},{"issue":"4","key":"10.1016\/j.xphs.2021.10.007_bib0020","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/IGC.0000000000000125","article-title":"Lymph node count at inguinofemoral lymphadenectomy and groin recurrences in vulvar cancer","volume":"24","author":"Van Beekhuizen","year":"2014","journal-title":"Int J Gynecol Cancer"},{"issue":"12","key":"10.1016\/j.xphs.2021.10.007_bib0021","doi-asserted-by":"crossref","first-page":"e3000486","DOI":"10.1371\/journal.pbio.3000486","article-title":"High-resolution 3D imaging and topological mapping of the lymph node conduit system","volume":"17","author":"Kelch","year":"2019","journal-title":"PLoS Biol."},{"issue":"3","key":"10.1016\/j.xphs.2021.10.007_bib0022","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1089\/lrb.2009.0029","article-title":"Lymph flow in instrumented dogs varies with exercise intensity","volume":"8","author":"Desai","year":"2010","journal-title":"Lymphat Res Biol"},{"issue":"8","key":"10.1016\/j.xphs.2021.10.007_bib0023","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S0090-9556(24)15240-3","article-title":"Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: a positive drug-drug interaction","volume":"27","author":"Kumar","year":"1999","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.xphs.2021.10.007_bib0024","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S0090-9556(24)14888-X","article-title":"In vitro metabolism of the HIV-1 protease inhibitor ABT-378: species comparison and metabolite identification","volume":"27","author":"Kumar","year":"1999","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"10.1016\/j.xphs.2021.10.007_bib0025","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1073\/pnas.92.7.2484","article-title":"ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans","volume":"92","author":"Kempf","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"10.1016\/j.xphs.2021.10.007_bib0026","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1023\/B:PHAM.0000041457.64638.8d","article-title":"Metabolism and disposition of the HIV-1 protease inhibitor lopinavir (ABT-378) given in combination with ritonavir in rats, dogs, and humans","volume":"21","author":"Kumar","year":"2004","journal-title":"Pharm Res"},{"issue":"6","key":"10.1016\/j.xphs.2021.10.007_bib0027","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1124\/mol.114.094862","article-title":"Characterization of ritonavir-mediated inactivation of cytochrome P450 3A4","volume":"86","author":"Rock","year":"2014","journal-title":"Mol Pharmacol"},{"issue":"6","key":"10.1016\/j.xphs.2021.10.007_bib0028","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1124\/dmd.110.037523","article-title":"Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir","volume":"39","author":"Kirby","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.xphs.2021.10.007_bib0029","unstructured":"AbbiVie. NDA - Clinical Pharmacology and Biopharmaceutical Review of Kaletra. Silver Spring, MD: Food and Drug Administration. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2000\/21-226_Kaletra_biopharmr_P1.pdf. Accessed October 7, 2020."},{"key":"10.1016\/j.xphs.2021.10.007_bib0030","series-title":"Drug Approval Package: VIREAD (Tenofovir Disoproxil Fumarate) Tablets","year":"2001"},{"issue":"9","key":"10.1016\/j.xphs.2021.10.007_bib0031","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1128\/AAC.42.9.2380","article-title":"Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults","volume":"42","author":"Deeks","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.xphs.2021.10.007_bib0032","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/psp4.12481","article-title":"Probenecid-boosted tenofovir: a physiologically-based pharmacokinetic model-informed strategy for on-demand HIV preexposure prophylaxis","volume":"9","author":"Liu","year":"2020","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"key":"10.1016\/j.xphs.2021.10.007_bib0033","series-title":"Drug Approval Package: COMPLERA (emtricitabine, rilpivirine, Tenofovir Disoproxil fumarate) Tablets","year":"2011"},{"issue":"3","key":"10.1016\/j.xphs.2021.10.007_bib0034","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0026-2862(76)90061-3","article-title":"The microvascular bed and capillary surface area in rat extensor hallucis proprius muscle (EHP)","volume":"11","author":"Myrhage","year":"1976","journal-title":"Microvasc Res"},{"issue":"3","key":"10.1016\/j.xphs.2021.10.007_bib0035","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1128\/AAC.42.3.612","article-title":"Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA","volume":"42","author":"Robbins","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.xphs.2021.10.007_bib0036","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jtbi.2003.09.002","article-title":"Complex patterns of viral load decay under antiretroviral therapy: influence of pharmacokinetics and intracellular delay","volume":"226","author":"Dixit","year":"2004","journal-title":"J Theor Biol"},{"issue":"10","key":"10.1016\/j.xphs.2021.10.007_bib0037","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1128\/AAC.00419-09","article-title":"Antiretroviral tissue kinetics: in vivo imaging using positron emission tomography","volume":"53","author":"Di Mascio","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.xphs.2021.10.007_bib0038","doi-asserted-by":"crossref","first-page":"46","DOI":"10.5625\/lar.2016.32.1.46","article-title":"Reference values of hematology, biochemistry, and blood type in cynomolgus monkeys from cambodia origin","volume":"32","author":"Choi","year":"2016","journal-title":"Lab Anim Res"},{"issue":"4","key":"10.1016\/j.xphs.2021.10.007_bib0039","article-title":"Metabolism And Disposition of the HIV-1 Protease Inhibitor Ritonavir (ABT-538) in Rats, Dogs, and Humans","volume":"25","author":"Denissen","year":"1997","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"10.1016\/j.xphs.2021.10.007_bib0040","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1002\/jps.23106","article-title":"Dermal clearance model for epidermal bioavailability calculations","volume":"101","author":"Ibrahim","year":"2012","journal-title":"J Pharm Sci"},{"issue":"5","key":"10.1016\/j.xphs.2021.10.007_bib0041","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1093\/jac\/dkq082","article-title":"Concentration-dependent effects and intracellular accumulation of HIV protease inhibitors in cultured CD4 T cells and primary human lymphocytes","volume":"65","author":"Janneh","year":"2010","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.xphs.2021.10.007_bib0042","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1177\/135965350400900520","article-title":"The plasma and intracellular steady-state pharmacokinetics of lopinavir\/ritonavir in HIV-1-infected patients","volume":"9","author":"Crommentuyn","year":"2004","journal-title":"Antivir Ther (Lond)"},{"issue":"2","key":"10.1016\/j.xphs.2021.10.007_bib0043","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1093\/jac\/dkq447","article-title":"Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection","volume":"66","author":"Anderson","year":"2011","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.xphs.2021.10.007_bib0044","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1021\/mp900036s","article-title":"Nucleotide analog prodrug, tenofovir disoproxil, enhances lymphoid cell loading following oral administration in monkeys","volume":"6","author":"Durand-Gasselin","year":"2009","journal-title":"Mol Pharm"},{"issue":"3","key":"10.1016\/j.xphs.2021.10.007_bib0045","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1124\/jpet.119.259150","article-title":"Antiretroviral Drug concentrations in lymph nodes: a cross-species comparison of the effect of drug transporter expression, viral infection, and sex in humanized mice, nonhuman primates, and humans","volume":"370","author":"Burgunder","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"10.1016\/j.xphs.2021.10.007_bib0046","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1128\/AAC.49.5.2093-2094.2005","article-title":"Pharmacokinetics of tenofovir in breast milk of lactating rhesus macaques","volume":"49","author":"Van Rompay","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.xphs.2021.10.007_bib0047","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2020.07.046","article-title":"Lymphatic targeting by albumin-hitchhiking: applications and optimisation","volume":"327","author":"Abdallah","year":"2020","journal-title":"J Control Release"},{"issue":"9","key":"10.1016\/j.xphs.2021.10.007_bib0048","doi-asserted-by":"crossref","first-page":"4980","DOI":"10.1128\/AAC.01095-12","article-title":"Compared to subcutaneous tenofovir, oral tenofovir disoproxyl fumarate administration preferentially concentrates the drug into gut-associated lymphoid cells in simian immunodeficiency virus-infected macaques","volume":"56","author":"Rompay","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.xphs.2021.10.007_bib0049","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1023\/A:1015880819328","article-title":"Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration","volume":"7","author":"Supersaxo","year":"1990","journal-title":"Pharm. Res."},{"issue":"10","key":"10.1016\/j.xphs.2021.10.007_bib0050","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11095-020-02888-8","article-title":"Novel long-acting drug combination nanoparticles composed of gemcitabine and paclitaxel enhance localization of both drugs in metastatic breast cancer nodules","volume":"37","author":"Yu","year":"2020","journal-title":"Pharm. Res."},{"key":"10.1016\/j.xphs.2021.10.007_bib0051","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.3389\/fphar.2020.603242","article-title":"Bictegravir plus tenofovir alafenamide nanoformulation as a long-acting pre-exposure prophylaxis regimen: application of modeling to design non-human primate pharmacokinetic experiments","volume":"11","author":"Perazzolo","year":"2020","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.xphs.2021.10.007_bib0052","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.xphs.2020.11.019","article-title":"Systems and clinical pharmacology of COVID-19 therapeutic candidates: a clinical and translational medicine perspective","volume":"110","author":"Perazzolo","year":"2021","journal-title":"J Pharm Sci"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354921005475?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354921005475?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:36:49Z","timestamp":1758361009000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354921005475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S0022354921005475"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2021.10.007","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Physiologically Based Pharmacokinetic Modeling of 3 HIV Drugs in Combination and the Role of Lymphatic System after Subcutaneous Dosing. Part 1: Model for the Free-Drug Mixture","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2021.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc. on behalf of American Pharmacists Association.","name":"copyright","label":"Copyright"}]}}